Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402685 | 0.83 | CCNA2 (0.52) | CCNA2CDK2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11969404 | 0.76 | GAA (0.49) | ALDH1A1SMN1; SMN2LMNATHRBMEN1 | |
| SCHEMBL3409177 | 0.73 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNATHRBNPC1 | |
| SCHEMBL3407076 | 0.73 | PRKCI (0.57) | CCNA2CDK2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL1242243 | 0.71 | ALDH1A1 (0.71) | ALDH1A1LMNATHRBMEN1KMT2A | |
| SCHEMBL29915528 | 0.71 | ALDH1A1 (0.71) | ALDH1A1LMNATHRBMEN1KMT2A | |
| SCHEMBL7996780 | 0.71 | MAPK1 (0.42) | — | |
| SCHEMBL30610259 | 0.71 | MAPK1 (0.42) | — | |
| SCHEMBL8693815 | 0.70 | DHODH (0.52) | CCNA2CDK2ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1106964 | 0.69 | HDAC1 (0.62) | ALDH1A1SMN1; SMN2LMNATHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| CN-102036961-B | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2014-02-26 | — | — | CN | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-102036961-A | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | CCNA2 2012/4885CDK2 3662/4885ALDH1A1 150/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | CCNA2 2012/4885CDK2 3662/4885ALDH1A1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.